Aravive Inc (NASDAQ:ARAV) CEO Jay Shepard sold 4,004 shares of Aravive stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $6.82, for a total value of $27,307.28.
Shares of NASDAQ ARAV opened at $6.79 on Friday. The business’s 50 day moving average is $6.66 and its two-hundred day moving average is $6.31. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.28 and a quick ratio of 11.28. Aravive Inc has a 1-year low of $3.07 and a 1-year high of $9.72.
Aravive (NASDAQ:ARAV) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.27) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.54) by $0.27. The company had revenue of $3.05 million for the quarter, compared to the consensus estimate of $1.00 million. On average, research analysts predict that Aravive Inc will post -1.79 EPS for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of ARAV. Artal Group S.A. increased its stake in Aravive by 20.0% during the second quarter. Artal Group S.A. now owns 307,466 shares of the company’s stock worth $1,845,000 after acquiring an additional 51,197 shares during the last quarter. Renaissance Technologies LLC increased its stake in Aravive by 13.8% during the second quarter. Renaissance Technologies LLC now owns 148,265 shares of the company’s stock worth $890,000 after acquiring an additional 18,017 shares during the last quarter. BlackRock Inc. increased its stake in Aravive by 5.8% during the second quarter. BlackRock Inc. now owns 173,943 shares of the company’s stock worth $1,044,000 after acquiring an additional 9,544 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Aravive by 4.7% during the second quarter. Vanguard Group Inc. now owns 159,034 shares of the company’s stock worth $955,000 after acquiring an additional 7,200 shares during the last quarter. 28.35% of the stock is currently owned by institutional investors.
Several equities research analysts have recently issued reports on the company. Piper Jaffray Companies set a $15.00 target price on Aravive and gave the stock a “buy” rating in a report on Friday, September 27th. HC Wainwright initiated coverage on Aravive in a research note on Thursday. They set a “buy” rating and a $18.00 price objective on the stock. ValuEngine raised Aravive from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, October 2nd. Finally, Zacks Investment Research cut Aravive from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $13.38.
Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.
Recommended Story: What are no-load funds?
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.